Announcements Trials
Browse Landscape

Phase

Phase 3 29Phase 2 16Phase 4 12Phase NA 6Phase 2/3 3Phase 1/2 3Phase 1 3

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Genitourinary 2Sarcoma 1

Conditions

Breast Neoplasms 2Metastatic Breast Cancer With Bone Involvement 1

Interventions

Capecitabine 17Paclitaxel 16Docetaxel 13Carboplatin 12Cyclophosphamide 11Gemcitabine 9Epirubicin 9Trastuzumab 8Letrozole 8Doxorubicin 7pertuzumab 5Cisplatin 5Vinorelbine 4130-nm albumin-bound paclitaxel 4exemestane 3Zoledronic Acid 3Tamoxifen 3Neoadjuvant Therapy 3Lapatinib 3Injections 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3pyrotinib 2palbociclib 2camrelizumab 2apatinib 2Thiotepa 2Taxes 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Zoledronic Acid × Breast × Clear all
NCT01344967 2015-06-23

SuBDuE

University Health Network, Toronto

Phase 2/3 Completed
21 enrolled
Breast

Metastatic Breast Cancer With Bone Involvement

NCT01654367 2012-07-31

esozao

Tianjin Medical University

Phase 2/3 Unknown
300 enrolled
Breast

Breast Neoplasms

NCT00524849 2010-09-14

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Fudan University

Phase 2/3 Completed
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡